Department of Neurosurgery, Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Neuro Oncol. 2018 Oct 9;20(11):1494-1504. doi: 10.1093/neuonc/noy082.
Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material.
Human monocyte-derived macrophages were co-cultured with Delta24-RGD-infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD-treated GBM patient were compared with 5 control GBM patient samples by flow cytometry.
Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD-infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD-treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD-treated patient showed significantly greater M1 characteristics than in control GBM tissue.
Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.
免疫抑制性促肿瘤 M2 巨噬细胞在胶质母细胞瘤(GBM)的发病机制、进展和治疗耐药中起着重要作用,并为治疗提供了靶点。最近的研究表明,溶瘤病毒治疗在小鼠模型中可以使这些 M2 巨噬细胞向促炎和抗肿瘤的 M1 表型转变。在这里,我们使用体外模型和患者标本研究了溶瘤病毒 Delta24-RGD 在人类中的作用。
人单核细胞来源的巨噬细胞与 Delta24-RGD 感染的原代胶质瘤干细胞样细胞(GSCs)共培养,并分析其免疫表型、细胞因子表达和分泌谱。分析了 18 名接受 Delta24-RGD 治疗的患者的脑脊液(CSF)中的炎症细胞因子水平,并确定了这些 CSF 样本对体外巨噬细胞表型的影响。此外,还通过流式细胞术比较了接受 Delta24-RGD 治疗的 GBM 患者切除标本中的肿瘤巨噬细胞与 5 名对照 GBM 患者样本。
与 Delta24-RGD 感染的 GSCs 共培养的人单核细胞来源的 M2 巨噬细胞向 M1 表型转变,同时伴有促炎基因表达和细胞因子产生。这种表型转变是由肿瘤产生的可溶性因子的变化和病毒颗粒的存在协同作用引起的。来自接受 Delta24-RGD 治疗的 GBM 患者的 CSF 样本显示出促炎微环境的细胞因子水平。此外,接受 Delta24-RGD 治疗的患者中的肿瘤巨噬细胞显示出比对照 GBM 组织中更大的 M1 特征。
这些体外和患者研究表明,局部 Delta24-RGD 治疗可能为促进人类 GBM 中促肿瘤 M2 巨噬细胞向 M1 的长期转变提供一种治疗工具,诱导促炎和潜在的肿瘤损害微环境。